Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.
Inhibitory effects of ranitidine, a new H2-receptor antagonist, and cimetidine on histamine and pentagastrin-induced gastric secretion have been compared in duodenal ulcer patients. Compared with cimetidine, ranitidine was found to be about 6-8 times a more potent inhibitor of gastric acid secretion, the inhibition of histamine-induced secretion being competitive, whereas that of pentagastrin-induced secretion not competitive. Ranitidine was an effective inhibitor of pentagastrin-induced secretion 8-12 h after administration. When given in a dose inhibiting gastric secretion by over 90%, it did not affect pancreatic secretion induced by secretin and pancreozymin. The availability of ranitidine, a more powerful inhibitor of gastric secretion, provides an opportunity of a treatment alternative to cimetidine, for peptic ulcer and related diseases.
D000328:Adult; D002766:Cholecystokinin / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000503:physiopathology*; D005663:Furans / Q000008:administration & dosage / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism*; D006632:Histamine / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010189:Pancreatic Juice / Q000378:metabolism*; D010418:Pentagastrin / Q000494:pharmacology; D011899:Ranitidine; D012633:Secretin / Q000494:pharmacology
D005663:Furans; D006635:Histamine H2 Antagonists; D012633:Secretin; D002927:Cimetidine; D006632:Histamine; D011899:Ranitidine; D002766:Cholecystokinin; D010418:Pentagastrin